Litcius/Paper detail

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy, Maude Bouscambert‐Duchamp, Drifa Belhadi, Alpha Diallo, Christelle Delmas, Juliette Saillard, Aline Dechanet, Noémie Mercier, Axelle Dupont, Toni Alfaiate, François-Xavier Lescure, F. Raffi, François Goehringer, Antoine Kimmoun, Stéphane Jauréguiberry, Jean Reignier, Saad Nseir, François Danion, Raphaël Clère-Jehl, Kévin Bouiller, Jean-Christophe Navellou, Violaine Tolsma, André Cabie, Clément Dubost, Johan Courjon, Sylvie Leroy, Joy Mootien, Rostane Gaci, Bruno Mourvillier, Emmanuel Faure, Valérie Pourcher, Sébastien Gallien, Odile Launay, Karine Lacombe, Jean‐Philippe Lanoix, Alain Makinson, Guillaume Martin‐Blondel, Lila Bouadma, Élisabeth Botelho-Nevers, Amandine Gagneux‐Brunon, Olivier Épaulard, Lionel Piroth, Florent Wallet, Jean‐Christophe Richard, Jean Reuter, Thérèse Staub, Bruno Lina, Marion Noret, Claire Andréjak, Minh Lê, Gilles Peytavin, Maya Hites, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentré

2021Clinical Microbiology and Infection107 citationsDOIOpen Access PDF

Topics & Concepts

Lopinavir/ritonavirLopinavirRitonavirHydroxychloroquineMedicineCoronavirus disease 2019 (COVID-19)Randomized controlled trialVirologyOpen label2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PharmacologyInternal medicineHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyInfectious disease (medical specialty)OutbreakDiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 | Litcius